Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Purpose: This multicenter study, to our knowledge, is the first phase III trial to compare trabectedin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma after prior therapy with an anthracycline and at least one additional systemic regimen. Patients and Methods: Patients were randomly assigned in a 2:1 ratio to receive trabectedin or dacarbazine intravenously every 3 weeks. The primary end point was overall survival (OS), secondary end points were disease control—progression-free survival (PFS), time to progression, objective response rate, and duration of response—as well as safety and patient-reported symptom scoring. Results: A total of 518 patients were enrolled and randomly assigned to either trabectedin (n = 345) or dacarbazine (n = 173). In the final analysis of PFS, trabectedin administration resulted in a 45% reduction in the risk of disease progression or death compared with dacarbazine (median PFS for trabectedin v dacarbazine, 4.2 v 1.5 months; hazard ratio, 0.55; P < .001); benefits were observed across all preplanned subgroup analyses. The interim analysis of OS (64% censored) demonstrated a 13% reduction in risk of death in the trabectedin arm compared with dacarbazine (median OS for trabectedin v dacarbazine, 12.4 v 12.9 months; hazard ratio, 0.87; P = .37). The safety profiles were consistent with the well-characterized toxicities of both agents, and the most common grade 3 to 4 adverse effects were myelosuppression and transient elevation of transaminases in the trabectedin arm. Conclusion: Trabectedin demonstrates superior disease control versus conventional dacarbazine in patients who have advanced liposarcoma and leiomyosarcoma after they experience failure of prior chemotherapy. Because disease control in advanced sarcomas is a clinically relevant end point, this study supports the activity of trabectedin for patients with these malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
Self-citationJudson, I., Verweij, J., Gelderblom, H., Hartmann, J. T., Schöffski, P., Blay, J.-Y., Kerst, J. M., Sufliarsky, J., Whelan, J., Hohenberger, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70063-4 · Cited by 1,183
Soft-Tissue Sarcomas in Adults
Clark, M. A., Fisher, C., Judson, I., & Thomas, J. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041866 · Cited by 907
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.008 · Cited by 864
Maki, R. G., Wathen, J. K., Patel, S. R., Priebat, D. A., Okuno, S. H., Samuels, B., Fanucchi, M., Harmon, D. C., Schuetze, S. M., Reinke, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4117 · Cited by 742
Self-citationSleijfer, S., Ray-Coquard, I., Papai, Z., Le Cesne, A., Scurr, M., Schöffski, P., Collin, F., Pandite, L., Marreaud, S., De Brauwer, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3223 · Cited by 679
Van Glabbeke, M., van Oosterom, A. T., Oosterhuis, J. W., Mouridsen, H., Crowther, D., Somers, R., Verweij, J., Santoro, A., Buesa, J., & Tursz, T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.150 · Cited by 608
Demetri, G. D., Chawla, S. P., von Mehren, M., Ritch, P., Baker, L. H., Blay, J. Y., Hande, K. R., Keohan, M. L., Samuels, B. L., Schuetze, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0088 · Cited by 538
Self-citationSantoro, A., Tursz, T., Mouridsen, H., Verweij, J., Steward, W., Somers, R., Buesa, J., Casali, P., Spooner, D., & Rankin, E. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1537 · Cited by 526
Grosso, F., Jones, R. L., Demetri, G. D., Judson, I. R., Blay, J.-Y., Le Cesne, A., Sanfilippo, R., Casieri, P., Collini, P., Dileo, P., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70175-4 · Cited by 454
Self-citation
Cited by
Casali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brodowicz, T., Broto, J. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy096 · Cited by 1,614
Self-citationTawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452
Self-citationSoft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
von Mehren, M., Kane, J. M., Agulnik, M., Bui, M. M., Carr-Ascher, J., Choy, E., Connelly, M., Dry, S., Ganjoo, K. N., Gonzalez, R. J., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0035 · Cited by 1,182
Self-citationGronchi, A., Miah, A. B., Dei Tos, A. P., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.07.006 · Cited by 1,115
Self-citationSchöffski, P., Chawla, S., Maki, R. G., Italiano, A., Gelderblom, H., Choy, E., Grignani, G., Camargo, V., Bauer, S., Rha, S. Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01283-0 · Cited by 778
Self-citationD'Angelo, S. P., Mahoney, M. R., Van Tine, B. A., Atkins, J., Milhem, M. M., Jahagirdar, B. N., Antonescu, C. R., Horvath, E., Tap, W. D., Schwartz, G. K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30006-8 · Cited by 759
Self-citationSoft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, J. M., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0025 · Cited by 736
Self-citationGamboa, A. C., Gronchi, A., & Cardona, K. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21605 · Cited by 524
UK guidelines for the management of soft tissue sarcomas
Dangoor, A., Seddon, B., Gerrand, C., Grimer, R., Whelan, J., & Judson, I. (2016) · Clinical Sarcoma Research · doi:10.1186/s13569-016-0060-4 · Cited by 477
Clinical and Molecular Spectrum of Liposarcoma
Lee, A. T. J., Thway, K., Huang, P. H., & Jones, R. L. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.9598 · Cited by 372
Self-citationTumor-Associated Macrophages: Implications in Cancer Immunotherapy
Petty, A. J., & Yang, Y. (2017) · Immunotherapy · doi:10.2217/imt-2016-0135 · Cited by 363
Chi, Y., Fang, Z., Hong, X., Yao, Y., Sun, P., Wang, G., Du, F., Sun, Y., Wu, Q., Qu, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3766 · Cited by 334
Tap, W. D., Papai, Z., Van Tine, B. A., Attia, S., Ganjoo, K. N., Jones, R. L., Schuetze, S., Reed, D., Chawla, S. P., Riedel, R. F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30381-9 · Cited by 302
Self-citationSoft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Conrad, E. U., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0078 · Cited by 297
Self-citationMartin-Broto, J., Hindi, N., Grignani, G., Martinez-Trufero, J., Redondo, A., Valverde, C., Stacchiotti, S., Lopez-Pousa, A., D'Ambrosio, L., Gutierrez, A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001561 · Cited by 183
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors
Wagner, A. J., Banerji, U., Mahipal, A., Somaiah, N., Hirsch, H., Fancourt, C., Johnson-Levonas, A. O., Lam, R., Meister, A. K., Russo, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7117 · Cited by 120
Pollack, S. M. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1419068 · Cited by 47
Schulte, B., Mohindra, N., Milhem, M., Attia, S., Robinson, S., Monga, V., Hirbe, A. C., Oppelt, P., Charlson, J., Helenowski, I., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01448-0 · Cited by 19
Self-citationAngeles, C. V., Velez, A., Rios, J., Laxa, B., Shum, D., Ruiz, P. D., Shen, Y., Ostrovnaya, I., Gularte-Mérida, R., Nacev, B. A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2486 · Cited by 13
Metadata
- Authors
- Demetri, G. D., von Mehren, M., Jones, R. L., Hensley, M. L., Schuetze, S. M., Staddon, A., Milhem, M., Elias, A., Ganjoo, K., Tawbi, H., Van Tine, B. A., Spira, A., Dean, A., Khokhar, N. Z., Park, Y. C., Knoblauch, R. E., Parekh, T. V., Maki, R. G., & Patel, S. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-03-10
- Volume
- 34
- Issue
- 8
- Pages
- 786-793
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1955072209
- Cited by
- 841
- References
- 29
- FWCI
- 56.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.